PLIANT THERAPEUTICS, INC. Depreciation
PLIANT THERAPEUTICS, INC. (PLRX) reported Depreciation of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-11
- PLIANT THERAPEUTICS, INC. depreciation for the quarter ending 2026-06-30 was $200.00K, a 50.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. depreciation for the quarter ending 2026-03-31 was $264.00K, a 41.07% decline year-over-year.
- PLIANT THERAPEUTICS, INC. depreciation for the quarter ending 2025-12-31 was $365.00K, a 20.31% decline year-over-year.
- PLIANT THERAPEUTICS, INC. depreciation for the quarter ending 2025-09-30 was $400.00K, a 20.00% decline year-over-year.
- PLIANT THERAPEUTICS, INC. depreciation for fiscal 2025 was $1.70M, a 20.19% decline from fiscal 2024.
- PLIANT THERAPEUTICS, INC. depreciation for fiscal 2024 was $2.13M, a 15.43% increase from fiscal 2023.
- PLIANT THERAPEUTICS, INC. depreciation for fiscal 2023 was $1.84M, a 0.99% increase from fiscal 2022.
- PLIANT THERAPEUTICS, INC. depreciation for fiscal 2022 was $1.82M, a 18.76% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-11 | $513.00K 10-Q · filed 2026-08-11 | $829.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.23M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $264.00K 10-Q · filed 2026-05-11 | $629.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.03M derived: sum of 3 quarters · filed 2026-05-11 | $1.43M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $765.00K derived: sum of 2 quarters · filed 2026-03-11 | $1.17M derived: sum of 3 quarters · filed 2026-08-11 | $1.70M 10-K · filed 2026-03-11 | |
| 2025-09-30 | $400.00K 10-Q · filed 2025-11-06 | $800.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.33M 10-Q · filed 2025-11-06 | $1.71M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-11 | $895.00K 10-Q · filed 2026-08-11 | $1.31M derived: sum of 3 quarters · filed 2026-08-11 | $1.81M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $448.00K 10-Q · filed 2026-05-11 | $906.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.41M derived: sum of 3 quarters · filed 2026-05-11 | $2.01M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $458.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $958.00K derived: sum of 2 quarters · filed 2026-03-11 | $1.56M derived: sum of 3 quarters · filed 2026-03-11 | $2.13M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $500.00K 10-Q · filed 2025-11-06 | $1.10M derived: sum of 2 quarters · filed 2025-11-06 | $1.67M 10-Q · filed 2025-11-06 | $2.08M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $600.00K 10-Q · filed 2025-08-07 | $1.14M 10-Q · filed 2025-08-07 | $1.58M derived: sum of 3 quarters · filed 2025-08-07 | $2.08M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $513.00K 10-Q · filed 2025-05-08 | $977.00K derived: sum of 2 quarters · filed 2025-05-08 | $1.48M derived: sum of 3 quarters · filed 2025-05-08 | $1.88M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $464.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $964.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.36M derived: sum of 3 quarters · filed 2025-03-03 | $1.84M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-07 | $900.00K derived: sum of 2 quarters · filed 2024-11-07 | $1.38M 10-Q · filed 2024-11-07 | $1.81M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-06-30 | $400.00K 10-Q · filed 2024-08-07 | $929.00K 10-Q · filed 2024-08-07 | $1.31M derived: sum of 3 quarters · filed 2025-03-03 | $1.81M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2023-03-31 | $452.00K 10-Q · filed 2024-05-06 | $907.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.41M derived: sum of 3 quarters · filed 2025-03-03 | $1.81M derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | $455.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $955.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.35M derived: sum of 3 quarters · filed 2025-03-03 | $1.82M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-09 | $900.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.37M 10-Q · filed 2023-11-09 | $1.77M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $400.00K 10-Q · filed 2023-08-09 | $500.00K 10-Q · filed 2022-08-08 | $914.00K 10-Q · filed 2023-08-09 | $1.27M derived: sum of 3 quarters · filed 2024-02-27 | $1.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $455.00K 10-Q · filed 2023-05-09 | $873.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.27M derived: sum of 3 quarters · filed 2024-02-27 | $1.67M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $818.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.22M derived: sum of 3 quarters · filed 2024-02-27 | $1.53M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $400.00K 10-Q · filed 2022-11-08 | $800.00K derived: sum of 2 quarters · filed 2022-11-08 | $1.12M 10-Q · filed 2022-11-08 | $1.51M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-08 | $729.00K 10-Q · filed 2022-08-08 | $1.11M derived: sum of 3 quarters · filed 2022-08-08 | $1.41M derived: sum of 4 quarters · filed 2022-08-08 | |
| 2021-03-31 | $359.00K 10-Q · filed 2022-05-09 | $706.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.01M derived: sum of 3 quarters · filed 2022-05-09 | $1.31M derived: sum of 4 quarters · filed 2022-05-09 | |
| 2020-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $647.00K derived: sum of 2 quarters · filed 2022-03-01 | $947.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.31M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $300.00K 10-Q · filed 2021-11-09 | $600.00K derived: sum of 2 quarters · filed 2021-11-09 | $963.00K 10-Q · filed 2021-11-09 | $1.20M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $300.00K 10-Q · filed 2021-08-09 | $633.00K 10-Q · filed 2021-08-09 | $902.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.20M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $312.00K 10-Q · filed 2021-05-10 | $602.00K derived: sum of 2 quarters · filed 2022-03-01 | $902.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.10M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $290.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $590.00K derived: sum of 2 quarters · filed 2022-03-01 | $790.00K derived: sum of 3 quarters · filed 2022-03-01 | $1.11M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $300.00K 10-Q · filed 2020-11-10 | $500.00K derived: sum of 2 quarters · filed 2020-11-10 | $823.00K 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $200.00K 10-Q · filed 2020-08-11 | $536.00K 10-Q · filed 2020-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |